Form 4: Revolution Medicines' CEO Exercises Options and Sells Shares Under 10b5-1 Plan

Mark A. Goldsmith, CEO of Revolution Medicines, exercised stock options and sold shares of common stock on August 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On August 1, 2024, Mark A. Goldsmith, the CEO of Revolution Medicines, exercised stock options to acquire 10,000 shares of common stock at a price of $4.09 per share.
• Simultaneously, Goldsmith sold 6,783 shares at a weighted average price of $45.6004 and 3,217 shares at a weighted average price of $46.4779.
• These transactions were executed under a 10b5-1 trading plan adopted on December 1, 2023.
• Following these transactions, Goldsmith directly owns 311,885 shares of Revolution Medicines' common stock, including 210,375 restricted stock units.
• He also indirectly owns 25,424 shares through the Jonathan Goldsmith Revocable Trust, 25,424 shares through the Rebecca Eve Goldsmith Trust, and 465,604 shares through the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy. The CEO exercising options and selling shares is a common practice and doesn't necessarily indicate a positive or negative outlook for the company.

Positives

• The CEO's transactions are being conducted under a pre-arranged 10b5-1 trading plan, which can reassure investors that the sales are not based on insider information.

Risks

• Executive stock sales, even under a 10b5-1 plan, can sometimes be perceived negatively by investors.

Industry Context

Executive stock transactions are common in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid insider trading concerns. Investors often monitor these transactions for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals, to manage their personal finances while avoiding accusations of insider trading.
• The size and frequency of executive stock transactions can vary widely depending on the company's size, stage of development, and compensation policies.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential dilution from the option exercise and the selling pressure from the stock sales.

Key Dates